REG - Futura Medical PLC - Futura Medical Notice of Preliminary Results 2021

Futura MedicalAnnouncement

14/04/2022 16:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220414:nRSN4718Ia&default-theme=true

RNS Number : 4718I  Futura Medical PLC  14 April 2022

 

 

14 April 2022

 

  Futura Medical plc

("Futura" or the "Company")

Notice of Preliminary Results 2021

 

Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), pharmaceutical
company developing a portfolio of innovative products based on its
proprietary, transdermal DermaSys® drug delivery technology and currently
focused on sexual health and pain, will announce its preliminary results for
the year ended 31 December 2021 on Tuesday, 26 April 2022.

 

James Barder, Chief Executive Officer, Angela Hildreth, Finance Director and
Chief Operating Officer, and Ken James, Executive Director and Head of
R&D, will host a webcast for analysts on the day of the results, which
will be made available within the investor centre section
(https://www.futuramedical.com/investor-centre/) of the Company's website.

 

 

-ENDS-

For further information please contact:

Futura Medical plc

James Barder, Chief Executive

Angela Hildreth, Finance Director and COO

Email: investor.relations@futuramedical.com
(mailto:Investor.relations@futuramedical.com)

Tel: +44 (0) 1483 685 670

www.futuramedical.com (http://www.futuramedical.com/)

 

Nominated Adviser and Sole Broker:

Liberum

Richard Lindley/ Phil Walker/ Kane Collings

Tel: +44 (0) 20 3100 2000

 

For media enquiries please contact:

Optimum Strategic Communications

Mary Clark/ Eva Haas/ Hollie Vile/ Zoe Bolt

Email: futuramedical@optimumcomms.com

Tel: +44 (0) 20 3922 0891

 

Notes to editors

 

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a
portfolio of innovative products based on its proprietary, transdermal
DermaSys(®) technology. Each DermaSys® formulation is separately patented
and specifically tailored for the selected indication and application, as well
as being optimised for clinical efficacy, safety, administration and patient
convenience. The products are developed for the prescription and consumer
healthcare markets as appropriate. Current therapeutic areas are sexual
health, including erectile dysfunction, and pain relief. Development and
commercialisation strategies are designed to maximise product differentiation
and value creation whilst minimising risk.

 

MED3000 is Futura's topical gel formulation that is a breakthrough treatment
for erectile dysfunction (ED) through a unique evaporative mode of action.
Futura has conducted a Phase 3 study using MED3000 in ED, referred to as
"FM57". This was a 1,000 patient, dose-ranging, multi-centre, randomised,
double blind, placebo-controlled, home use, parallel group study delivering
highly statistically significant results compared to pre-treatment baseline,
consistently meeting all co-primary endpoints of IIEF, SEP2 and SEP3
(internationally accepted clinical trial endpoints in ED) with over 60% of
patients experiencing a clinically meaningful improvement in their ED.
MED3000 also begins to work immediately in some patients, with 60% of patients
seeing onset of their erection within 10 minutes of application. MED3000 is CE
marked in Europe and the UK as a clinically proven topical treatment
for adult men with erectile dysfunction.

 

Futura is based in Guildford, Surrey, and its shares trade on the AIM market
of the London Stock Exchange. www.futuramedical.com
(https://www.futuramedical.com/)

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORKZGMDDDFGZZM